Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Top Cited Papers
- 7 February 2014
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 15 (3), 323-332
- https://doi.org/10.1016/s1470-2045(14)70012-9
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving SorafenibJournal of Clinical Oncology, 2009
- Chemoimmunotherapy versus chemotherapy for metastatic malignant melanomaCochrane Database of Systematic Reviews, 2007
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study GroupJournal of Clinical Oncology, 2006
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III StudyJournal of Clinical Oncology, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trialsMelanoma Research, 2001
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999